Literature DB >> 27742591

The Multiple Facets of PRC2 Alterations in Cancers.

M Wassef1, R Margueron2.   

Abstract

Genome sequencing of large cohorts of tumors has revealed that mutations in genes encoding chromatin regulators are frequent in cancer. However, the precise contribution of these mutations to tumor development often remains elusive. Here, we review the current knowledge concerning the alterations of the Polycomb machinery in cancer, with a particular focus on the Polycomb repressive complex 2 (PRC2), a key chromatin modifier involved in the maintenance of transcriptional silencing. A broad variety of alterations can impair PRC2 activity; yet, overall, only one type of alteration is found in a given class of tumor. We discuss the potential impact of the various types of PRC2 alterations on gene expression. We propose that the distinct set of genes regulated by PRC2, depending on tumor etiology, constrain the type of alteration of PRC2 that can fuel tumor development. Beyond this specificity, we propose that PRC2 and, more generally, chromatin regulators act as gatekeepers of transcriptional integrity, a role that often confers a tumor-suppressive function.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EZH2; PRC2; cancer; chromatin; polycomb

Mesh:

Substances:

Year:  2016        PMID: 27742591     DOI: 10.1016/j.jmb.2016.10.012

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  20 in total

1.  Nucleation and Propagation of Heterochromatin by the Histone Methyltransferase PRC2: Geometric Constraints and Impact of the Regulatory Subunit JARID2.

Authors:  Eva J Ge; Krupa S Jani; Katharine L Diehl; Manuel M Müller; Tom W Muir
Journal:  J Am Chem Soc       Date:  2019-09-17       Impact factor: 15.419

2.  PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor.

Authors:  Katharine L Diehl; Eva J Ge; Daniel N Weinberg; Krupa S Jani; C David Allis; Tom W Muir
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

Review 3.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

4.  EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Authors:  Michel Wassef; Armelle Luscan; Setareh Aflaki; Dina Zielinski; Pascal W T C Jansen; H Irem Baymaz; Aude Battistella; Carole Kersouani; Nicolas Servant; Margaret R Wallace; Pierre Romero; Olivier Kosmider; Pierre-Alexandre Just; Mikaël Hivelin; Sébastien Jacques; Anne Vincent-Salomon; Michiel Vermeulen; Michel Vidaud; Eric Pasmant; Raphaël Margueron
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-13       Impact factor: 11.205

Review 5.  PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function.

Authors:  Xiuli Liu; Xin Liu
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

6.  EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.

Authors:  Xiaowen Guan; Houliang Deng; Un Lam Choi; Zhengfeng Li; Yiqi Yang; Jianming Zeng; Yunze Liu; Xuanjun Zhang; Gang Li
Journal:  Oncogene       Date:  2020-10-02       Impact factor: 9.867

7.  Enhancer of zeste homolog 2 (Ezh2) controls bone formation and cell cycle progression during osteogenesis in mice.

Authors:  Amel Dudakovic; Emily T Camilleri; Christopher R Paradise; Rebekah M Samsonraj; Martina Gluscevic; Carlo Alberto Paggi; Dana L Begun; Farzaneh Khani; Oksana Pichurin; Farah S Ahmed; Ranya Elsayed; Mohammed Elsalanty; Meghan E McGee-Lawrence; Marcel Karperien; Scott M Riester; Roman Thaler; Jennifer J Westendorf; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2018-06-13       Impact factor: 5.157

8.  Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.

Authors:  Sónia Carvalho; Micaela Freitas; Luís Antunes; Sara Monteiro-Reis; Marcia Vieira-Coimbra; Ana Tavares; Sofia Paulino; José Flávio Videira; Carmen Jerónimo; Rui Henrique
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-13       Impact factor: 4.553

9.  Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21.

Authors:  Tianyang Xu; Wenwei Jiang; Lin Fan; Qiuming Gao; Guodong Li
Journal:  Oncotarget       Date:  2017-09-08

10.  Growth Factor-Independent 1 Is a Tumor Suppressor Gene in Colorectal Cancer.

Authors:  Min-Shan Chen; Yuan-Hung Lo; Xi Chen; Christopher S Williams; Jessica M Donnelly; Zachary K Criss; Shreena Patel; Joann M Butkus; Julien Dubrulle; Milton J Finegold; Noah F Shroyer
Journal:  Mol Cancer Res       Date:  2019-01-03       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.